Analyst Josh Jennings from TD Cowen maintained a Buy rating on Boston Scientific (BSX – Research Report) and keeping the price target at $115.00.
Josh Jennings has given his Buy rating due to a combination of factors including the promising results from the Single Shot Champion trial. The trial demonstrated that Boston Scientific’s Farapulse PFA system is more effective in reducing atrial arrhythmia recurrence compared to a competing product from MDT.
The data, which was presented at the EHRA meeting and published in the New England Journal of Medicine, highlighted the system’s superior efficacy and comparable safety profile. These findings suggest that Farapulse could be a more competitive and efficient option for treating paroxysmal AFib, supporting a positive outlook for Boston Scientific’s stock.
In another report released yesterday, DBS also maintained a Buy rating on the stock with a $130.00 price target.